HLE Glascoat Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Weak quarter, second-half recovery bet: Domestic glassline revenue fell on customer order deferrals, but management expects the historical pattern of a stronger second half to hold, targeting full-year revenue of INR1,100-1,150 crores.
• Margins compressed across segments: Domestic glassline EBITDA margins fell on lower utilization (70-75% vs 85% last year), while ANFD margins took a one-time hit from employee incentives and Gujarat minimum-wage adjustments.
• Thaletec India launch opens a new premium tier: The German-engineered, customized reactor range has started booking orders in India and addresses needs no competitor currently serves, with no cannibalization of the core HLE portfolio.
• End-market mix is shifting: Agrochemicals remain muted, but specialty chemicals are steady and pharmaceuticals, slow for two years, are now picking up.
• What to watch next quarter: Whether the promised second-half dispatch acceleration materializes, the pace of margin recovery toward the 16-18% guided range, and the order ramp for Thaletec India.

Domestic Glassline: The Core Slowdown

• Order deferrals hit the top line: Certain customers pushed out orders, and that directly reduced dispatches in the quarter. Management frames this as a timing shift, not a cancellation cycle, and expects it to reverse in the second half as has been the historical trend.
• Utilization dropped sharply: Plant utilization fell to 70-75% from 85% a year ago, leaving more fixed costs to absorb and pressuring margins.
• Long-term margin anchor stated clearly: Management reiterated that the 20%-plus margins seen earlier were never sustainable and that 16% to 18% EBITDA is the long-term average for this business.

Ganjwala: "I believe even at the time when we had reported 20 plus percent margins, we were quite clear that these are not long-term sustainable. We do believe that the long-term sustainable margins in this business are between 16% to 18% and that we still believe would be the long-term average."

Filtration & Drying: Margin Reset, Order Book Intact

• ANFD margin drop was largely one-time: The quarter absorbed the full-year effect of employee incentives and increments, plus a catch-up adjustment for Gujarat minimum wages. Management expects the current employee-cost level to sustain, implying the hit does not repeat at this scale.
• Silvassa unit clouds comparability: The prior-period comparator included commissioning of the Greenfield Silvassa project, so the margin contraction is partly a base-effect story.
• Competitive position holds: The company sees no serious competition from GMM in filtration and drying, continues to hold predominant market share, and describes the order book as robust.
• Normalized margin guide: In a more normalized market, 16% to 18% EBITDA margins are a fair assessment for this segment too.

Thaletec India: A Premium Layer Without Cannibalization

• Product launched and already booking orders: Thaletec products were introduced in India two to three months ago, the initial response is encouraging, and confirmed orders have started flowing with deliveries scheduled.
• Customized, not comparable: The Thaletec reactor is a highly customized, value-added offering versus standardized current products, so direct price comparisons are not meaningful. Management did indicate a 10% to 40% premium range when pressed.
• No overlap with the HLE range: Most Thaletec features are unrivaled in the Indian market, HLE does not offer those solutions, and they are simply not available to Indian customers from other sources. The launch opens new opportunities rather than eating into the existing HLE franchise.
• Made in India: These reactors will be manufactured domestically.

Aalap Patel: "So I think most of the features in the Thaletec product are actually unrivaled. So not only does HLE not have those solutions, but these solutions are simply, in most cases, not available to an Indian customer. So it really doesn't cannibalize on the HLE market. It simply opens up newer opportunities."

End-Market Mix: Pharma Turning, Agro Still Muted

• Agrochemicals the weakest link: The industry is largely muted, with customers deferring orders and staying quiet.
• Niche pigments and colors just stirring: The segment has started picking up but is nowhere close to year-ago levels; companies that had completely stopped investing are only just beginning to return.
• Specialty chemicals steady: This segment is at a normal level, doing good, with reasonable order flows.
• Pharmaceuticals the bright spot: The industry was slow over the last two years and is now picking up; management expects order flow from the pharma sector to increase, and believes the share of API pharma in the business will rise going forward.

Harsh Patel: "The specialty chemicals right now looks like they are at a normal level. They are in fact doing good. And we are expect, I mean, experiencing reasonable order flows from them. And we expect the pharmaceutical industry, which was kind of, relatively speaking, slow over the last two years, is now picking up and we expect order flow from the pharmaceutical sector."

Germany & Thaletec Europe

• German market healthy: The overall market situation in Germany is quite healthy, with a strong order book and a strong inquiry pipeline, though different subcategories have different scenarios.
• Thaletec Germany margin profile lower: Standalone Thaletec Germany margins are expected in the 14% to 15% EBITDA range, below the 16-18% guided for the domestic glassline and F&D businesses.

Balance Sheet, M&A and Capital Allocation

• Kinam consolidation creates inventory distortion: Kinam Engineering's balance sheet was consolidated from 30 September, but its revenue only from 26 September (4-5 days). The full inventory but negligible revenue inflates reported inventory days and does not accurately reflect operations. The underlying inventory build also reflects a good order book and production for the seasonally stronger second half.
• Kinam stake moving to 70%: The company will invest another INR77.5 crores to acquire the balance 34.44% in Kinam via a share issue to the erstwhile promoters, with no cash outflow. A valuation is underway and the scheme will go to the NCLT.
• No major capex ahead: Only normal maintenance capex of INR8-10 crores per year is planned; no new products or projects are on the table.
• Debt reduction priority: Significant cash flow can be directed to debt repayment next year.
• Promoter stake sale was a one-off: Promoters reduced some stake solely to bring a high-quality investor onto the shareholder list; they continue to hold a very healthy stake and have no plans to reduce further.

Ganjwala: "I don't think the intent was ever to reduce the stake. I think the promoters continue to hold a very healthy stake in the company and will continue to do so. The only intention was to bring in a high quality investor in the shareholder list."

Guidance & Commitments

Key Metrics